Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LF111 or drospirenone chewable tablets and bone mineral density in women using contraception
2020-000412-30Phase 3Active
- Sponsor
- Chemo
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of drospirenone in contraception (3 arms), sponsored by Chemo. Primary endpoint: Lumbar spine bone mineral density change after 12 months. Started May 2022; status: active.
02
Drugs
drospirenone
03
Conditions
contraception
Beyond the preview
Go deeper on 2020-000412-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000412-30.